Cumulative results for the total group and 3 subgroups of primary and secondary CD30– peripheral T/NK-cell lymphomas
. | Total . | Primary CTCL, large cell . | Primary CTCL, small/medium cell . | Concurrent CTCL* . |
|---|---|---|---|---|
| Patients, no. | 82 | 46 | 19 | 17 |
| Sex ratio, male-female | 50:32 | 33:13 | 6:13 | 11:6 |
| Age, median, y (range) | 68 (8-87) | 68 (20-87) | 69 (45-87) | 65 (8-85) |
| Extent of skin lesions, no. | ||||
| Solitary | 21 | 15 | 4 | 2 |
| Localized | 11 | 4 | 5 | 2 |
| Multifocal | 50 | 27 | 10 | 13 |
| Spontaneous remission, no. | ||||
| Absent | 69 | 39 | 13 | 16 |
| Partial | 10 | 6 | 4 | 1 |
| Complete | 3 | 1 | 2 | 0 |
| Initial therapy, no. | ||||
| Radiotherapy | 31 | 19 | 12 | 0 |
| Multiagent chemotherapy | 36† | 18‡ | 5 | 13§ |
| Excision | 2 | 2 | 0 | 0 |
| PUVA | 3 | 1 | 0 | 2 |
| Monochemotherapy | 6§ | 3 | 1§ | 2 |
| None | 4 | 3 | 1 | 0 |
| Result of initial therapy, no. | ||||
| Complete remission | 36 | 21 | 12 | 3 |
| Partial remission | 27 | 13 | 6 | 8 |
| No response/progression | 19 | 12 | 1 | 6 |
| Relapse, no. | ||||
| Skin only | 15 | 9 | 6 | 0 |
| Systemic | 58 | 34 | 7 | 17 |
| None | 9 | 3 | 6 | 0 |
| Follow-up, median, mo (range) | 19 (1-179) | 21 (1-118) | 47 (9-143) | 8 (1-179) |
| Current status, no. | ||||
| No evidence of disease | 12 | 4 | 7 | 1 |
| Alive with disease | 1 | 0 | 1 | 0 |
| Died of lymphoma | 60 | 37 | 8 | 15 |
| Died of other cause | 9 | 5 | 3 | 1 |
| Phenotype, no. | ||||
| CD4+/CD8- | 59 | 34 | 13 | 12 |
| CD4-/CD8+ | 12 | 6 | 4 | 2 |
| CD4-/CD8- | 9 | 5 | 2 | 2 |
| CD4+/CD8+ | 2 | 1 | 0 | 1 |
| Overall survival, % | ||||
| 5 y | 20 | 12 | 45 | 12 |
| 10 y | 8 | NR | 19 | NR |
| Median survival, mo | 21 | 22 | 56 | 8 |
. | Total . | Primary CTCL, large cell . | Primary CTCL, small/medium cell . | Concurrent CTCL* . |
|---|---|---|---|---|
| Patients, no. | 82 | 46 | 19 | 17 |
| Sex ratio, male-female | 50:32 | 33:13 | 6:13 | 11:6 |
| Age, median, y (range) | 68 (8-87) | 68 (20-87) | 69 (45-87) | 65 (8-85) |
| Extent of skin lesions, no. | ||||
| Solitary | 21 | 15 | 4 | 2 |
| Localized | 11 | 4 | 5 | 2 |
| Multifocal | 50 | 27 | 10 | 13 |
| Spontaneous remission, no. | ||||
| Absent | 69 | 39 | 13 | 16 |
| Partial | 10 | 6 | 4 | 1 |
| Complete | 3 | 1 | 2 | 0 |
| Initial therapy, no. | ||||
| Radiotherapy | 31 | 19 | 12 | 0 |
| Multiagent chemotherapy | 36† | 18‡ | 5 | 13§ |
| Excision | 2 | 2 | 0 | 0 |
| PUVA | 3 | 1 | 0 | 2 |
| Monochemotherapy | 6§ | 3 | 1§ | 2 |
| None | 4 | 3 | 1 | 0 |
| Result of initial therapy, no. | ||||
| Complete remission | 36 | 21 | 12 | 3 |
| Partial remission | 27 | 13 | 6 | 8 |
| No response/progression | 19 | 12 | 1 | 6 |
| Relapse, no. | ||||
| Skin only | 15 | 9 | 6 | 0 |
| Systemic | 58 | 34 | 7 | 17 |
| None | 9 | 3 | 6 | 0 |
| Follow-up, median, mo (range) | 19 (1-179) | 21 (1-118) | 47 (9-143) | 8 (1-179) |
| Current status, no. | ||||
| No evidence of disease | 12 | 4 | 7 | 1 |
| Alive with disease | 1 | 0 | 1 | 0 |
| Died of lymphoma | 60 | 37 | 8 | 15 |
| Died of other cause | 9 | 5 | 3 | 1 |
| Phenotype, no. | ||||
| CD4+/CD8- | 59 | 34 | 13 | 12 |
| CD4-/CD8+ | 12 | 6 | 4 | 2 |
| CD4-/CD8- | 9 | 5 | 2 | 2 |
| CD4+/CD8+ | 2 | 1 | 0 | 1 |
| Overall survival, % | ||||
| 5 y | 20 | 12 | 45 | 12 |
| 10 y | 8 | NR | 19 | NR |
| Median survival, mo | 21 | 22 | 56 | 8 |
Numbers are absolute number of patients uless indicated otherwise.
NR indicates not reached.
Both skin and extracutaneous disease at time of diagnosis.
Six of these patients received additional radiotherapy.
Five of these patients received additional radiotherapy.
One of these patients received additional radiotherapy.